Losartan effect on kidneys
Pro Research Analysisby 
Searched over 200M research papers
Losartan's Effect on Kidneys: A Comprehensive Review
Introduction to Losartan and Kidney Health
Losartan, an angiotensin II receptor antagonist, is widely used to manage hypertension and protect kidney function, particularly in patients with diabetes and chronic kidney disease (CKD). This article synthesizes findings from multiple studies to elucidate the effects of losartan on renal health.
Losartan and Diabetic Nephropathy
Renal Benefits in Type 2 Diabetes
Losartan has been shown to confer significant renal benefits in patients with type 2 diabetes and nephropathy. A large-scale study involving 1513 patients demonstrated that losartan reduced the incidence of a doubling of serum creatinine concentration by 25% and end-stage renal disease (ESRD) by 28% compared to placebo, without affecting the mortality rate . Additionally, losartan significantly decreased proteinuria by 35%, indicating its protective role against kidney damage .
Long-term Effects in American Indians
A follow-up analysis of a 6-year clinical trial in American Indians with type 2 diabetes revealed that early administration of losartan did not significantly slow the progression of diabetic kidney disease over an extended period. However, during the trial, losartan showed a trend towards reducing the risk of GFR decline, although this was not statistically significant .
Losartan in Acute Kidney Injury
Protective Effects Against Ischemia/Reperfusion Injury
In a study on male rats, losartan demonstrated protective effects against ischemia/reperfusion (I/R) injury, a major cause of acute kidney injury. The administration of losartan, either alone or in combination with angiotensin 1-7, significantly reduced levels of serum urea nitrogen, creatinine, and other markers of kidney damage, indicating its potential to mitigate I/R-induced renal injury .
Comparative Studies with Other Antihypertensives
Losartan vs. Amlodipine in CKD
A 12-month study comparing losartan with the calcium channel blocker amlodipine in patients with proteinuric CKD and hypertension found that while both drugs were equally effective in controlling blood pressure, only losartan significantly reduced urinary protein excretion. This reduction in proteinuria suggests that losartan offers superior renal protection compared to amlodipine .
Renal Hemodynamics and TGF-beta(1) Levels
In renal transplant recipients, losartan and amlodipine had different effects on renal hemodynamics and TGF-beta(1) plasma levels. Losartan maintained GFR and reduced glomerular hydrostatic pressure and filtration fraction, while also significantly lowering TGF-beta(1) levels, a key cytokine involved in fibrosis. In contrast, amlodipine increased GFR and did not affect TGF-beta(1) levels, highlighting losartan's additional benefits in managing chronic allograft nephropathy .
Mechanisms of Renoprotection
Reduction in Uric Acid Levels
Losartan's ability to lower serum uric acid (SUA) levels has been linked to its renoprotective effects. A post hoc analysis of a trial involving patients with type 2 diabetes and nephropathy showed that reductions in SUA during losartan therapy were associated with decreased renal risk, suggesting that part of losartan's renoprotective effect could be attributed to its impact on SUA levels .
Balancing Renal Dopaminergic and Renin-Angiotensin Systems
Losartan also helps prevent the imbalance between the renal dopaminergic system (RDS) and the renin-angiotensin system (RAS), which is associated with insulin resistance, hypertension, and kidney damage. In a study on fructose-overloaded rats, losartan prevented metabolic and hemodynamic alterations, reduced pro-inflammatory and pro-fibrotic markers, and mitigated renal damage, demonstrating its comprehensive protective effects on kidney function .
Conclusion
Losartan offers significant renal benefits, particularly in patients with type 2 diabetes and CKD. It reduces proteinuria, mitigates acute kidney injury, and balances key renal systems, providing comprehensive protection against kidney damage. While its long-term benefits in slowing GFR decline require further investigation, losartan remains a valuable therapeutic option for preserving kidney health.
Sources and full results
Most relevant research papers on this topic
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Losartan significantly reduces the risk of kidney damage and end-stage renal disease in patients with type 2 diabetes and nephropathy, while maintaining overall cardiovascular health.
Losartan prevents the imbalance between renal dopaminergic and renin angiotensin systems induced by fructose overload. l-Dopa/dopamine index as new potential biomarker of renal dysfunction.
Losartan effectively prevents the imbalance between the renin angiotensin and renal dopaminergic systems induced by fructose overload, preventing hypertension and kidney damage.
The Beneficial Effects of Allicin in Chronic Kidney Disease Are Comparable to Losartan
Allicin and losartan both have beneficial effects in chronic kidney disease, reducing hypertension, oxidative stress, and improving renal dysfunction.
Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial
Early losartan treatment showed no significant long-term benefit in slowing kidney disease progression in American Indians with type 2 diabetes.
DOI
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.
Losartan, but not amlodipine, decreased albumin excretion in hypertensive patients with non-diabetic nephropathy.
DOI